Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Avalyn Pharma Inc. (NASDAQ:AVLN) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $60.00.

A number of analysts have recently commented on the stock. Wall Street Zen cut shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Guggenheim assumed coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 price target on the stock. Evercore started coverage on Avalyn Pharma in a report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price objective on the stock. Zacks Research raised Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Finally, Morgan Stanley lifted their price target on Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th.

Institutional Investors Weigh In On Avalyn Pharma

A number of hedge funds have recently modified their holdings of AVLN. California State Teachers Retirement System purchased a new position in shares of Avalyn Pharma in the second quarter worth about $236,000. Braidwell LP purchased a new stake in Avalyn Pharma during the 2nd quarter valued at about $26,382,000. Montanova Capital LLC purchased a new stake in Avalyn Pharma during the 2nd quarter valued at about $82,402,000. Finally, Bank of New York Mellon Corp acquired a new stake in Avalyn Pharma in the 2nd quarter valued at about $1,321,000.

Avalyn Pharma Stock Performance

Avalyn Pharma stock opened at $37.39 on Friday. The firm has a market cap of $1.66 billion and a PE ratio of -1.64. The company has a fifty day moving average of $32.28. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma has a 1 year low of $24.15 and a 1 year high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. Sell-side analysts predict that Avalyn Pharma will post -3.81 EPS for the current year.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.